SEARCH RESULTS FOR:

A Brave New World: Energy Reform and the Mexican Chemical Industry

Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Mexico’s energy reform, national elections, the shale revolution in USA and Trump’s renegotiations of NAFTA all spell interesting times for Mexico’s chemical industry.

Saad Haroon

HEAD OF SEEDCARE APAC, SYNGENTA
Singapore Chemicals 2018
Seedcare APAC are seeking to promote seed treatment in Asia where it is not well understood.

David Ryan & Dave Shepherd

HEAD OF COMMERCIAL EXCELLENCE, APAC; LEADER, DIGITAL INNOVATION LAB & DIGITAL DELIVERY; INNOVATION LAB LEAD, SYNGENTA
Singapore Chemicals 2018
Syngenta’s Digital Innovation Lab in Singapore looks at how digital initiatives can increase smallholder productivity.

Sudhir Shenoy

CEO, DOW INDIA – DOW CHEMICAL
India Chemicals 2018 Pre-Release Edition
Dow Chemical in India speaks to GBR about its operations and the benefits that Sadara will bring.

Eric Pisani

CEO, SINTEX NP
Auvergne-Rhône-Alpes Aerospace 2018
Sintex is looking to expand its offering of thermoplastic composites to serve the aerospace sector worldwide.

H. S. Karangle

DIRECTOR GENERAL, INDIAN CHEMICAL COUNCIL
GBR speaks to the Indian Chemical Council about the prospects for the industry.

Industry 4.0: Can Auvergne-Rhône-Alpes keep up?

Auvergne-Rhône-Alpes Aerospace 2018
SMEs face more hurdles than OEMs in incorporating Industry 4.0, because, while adopting new technologies may offer clear long-term benefits, it can be a costly process.

Jocelyn Lardet

INDUSTRIAL DIRECTOR, JET CUT
Auvergne-Rhône-Alpes Aerospace 2018
Jet Cut is the European leader in water jet cutting services for metal and composite aerospace materials.

Doing Business in the DRC

GBR reports on the current situation in the DRC and the implications for mining investments.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS